Navigation Links
Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:10/22/2007

n patients with advanced solid tumors and in patients co-infected with HCV and HIV.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the protocol will not be approved, the risk that the company will experience delays or difficulties in enrolling patients in the study, and the risk that the results from this trial will not be consistent with the results of prior trials or pre-clinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and quarterly report on Form 10-Q for the quarter ended July 31, 2007. The company cautions investors not to place undue re
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 Nortek Security ... NTK ) and a leader in the ... today announced it acquired mobile personal emergency response ... held Numera, Inc. Headquartered in ... easily implemented, mobile PERS products and cloud-based software ...
(Date:6/30/2015)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... today announced it has submitted its fifth abbreviated new ... Administration (FDA) of 2015, which brings the Company,s total ... to twenty-seven. Jason Grenfell-Gardner , President ... current pipeline of twenty-seven submissions, exclusive of our four ...
(Date:6/30/2015)... new way for people to keep their family safe, while ... is being introduced to the world via an Indiegogo ... $70,000, which needs to be raised in order to bring ... device was inspired by the many scenarios people face in ... day. While medical alert bracelets have been around for years, ...
Breaking Medicine Technology:Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 2Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 3Nortek Security & Control Acquires Health and Wellness Technology Business from Numera 4IGI Laboratories, Inc. Announces Fifth ANDA Submission Of 2015 2Amyko Propels Medical Alert Bracelets Into the Modern Era 2
... , DENVER , Feb. 11 ... and marketer of diagnostic test kits, today filed its 2nd quarter ... the company,s revenues slightly declined during the quarter but slightly increased ... of the results highlighted by the report are as follows: , ...
... MOUNTAIN VIEW, Calif. , Feb. 11 Alexza Pharmaceuticals, ... & Drug Administration has accepted the AZ-004 NDA for filing and ... of October 11, 2010 .  Alexza filed the AZ-004 NDA ... for the rapid treatment of agitation in patients with schizophrenia or ...
Cached Medicine Technology:Corgenix Reports Second Quarter Fiscal 2010 Financial Results 2Corgenix Reports Second Quarter Fiscal 2010 Financial Results 3Corgenix Reports Second Quarter Fiscal 2010 Financial Results 4Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010 2Alexza Announces AZ-004 (Staccato(R) Loxapine) PDUFA Goal Date of October 11, 2010 3
(Date:6/30/2015)... ... June 30, 2015 , ... After many ... , finally its here, http://www.express-glasses.com is proud to announce its collaboration ... ask about shipping with DHL Express when calling or visiting the express glasses ...
(Date:6/30/2015)... ... June 30, 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier ... and added a new CEO, Mr. Darold Francis. The changes will help enhance the ... oils that customers have come to know and respect for over eight years. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates ... HRA Healthcare Research & Analytics , a consultative healthcare market research practice ... family of businesses. HRA offers quantitative and qualitative, custom and multi-client primary market ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... News Digest discussed the advantages that fat transfer procedures had over breast ... using fat transfer techniques create breasts that “look and feel natural,” have increased ...
(Date:6/30/2015)... ... 2015 , ... Board certified otolaryngologist Dr. Marcelo B. Antunes ... , Dr. Antunes is a fellowship trained facial plastic surgeon with ... to performing cosmetic and reconstructive surgery on the face, he enjoys treating patients ...
Breaking Medicine News(10 mins):Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 2Health News:Atlanta Otolaryngologist Dr. Marcelo Antunes Joins Northwest ENT and Allergy Center 3
... , Salad Bar to Be Donated to ... , , WASHINGTON, Aug. 19 The ... bar at its Fresh Festival event, September 9, in the Cannon House ... salad bar, stocked with fresh fruits and vegetables, will underscore the need ...
... , , NEW YORK, Aug. ... point-of-care digital signage network into major U.S. markets, including Detroit, Miami, ... demand for HMN,s services by healthcare providers and advertisers. Installations in ... markets is slated for the second half of 2009. HMN,s largest ...
... experts say , WEDNESDAY, Aug. 19 (HealthDay ... with the drug letrozole (Femara) increases survival after surgery ... confirms. , Both letrozole and tamoxifen have been used ... with hormone receptor-positive cancer, but whether one drug is ...
... , , , ... and BRISBANE, Calif., Aug. 19 Roche (SIX: ROG.VX; RO.S, OTCQX: ... that the first patient has been dosed in a Phase 2b ... in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). ...
... (August 19, 2009) Using a novel robot-assisted endoscopic ... of Medicine in Seoul, Korea, has successfully treated 200 ... which has several technical and cosmetic benefits that the ... the August issue of the Journal of the ...
... paraffin, suggest beeswax instead , WEDNESDAY, Aug. 19 (HealthDay ... ambiance, fragrance and light, may also contribute to air ... made from petroleum, are a source of known human ... to be presented Wednesday at the American Chemical Society,s ...
Cached Medicine News:Health News:United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 2Health News:United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 3Health News:Health Media Network Expands to New Markets 2Health News:Newer Drug Beats Tamoxifen for Older Breast Cancer Patients 2Health News:Newer Drug Beats Tamoxifen for Older Breast Cancer Patients 3Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 2Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 3Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 4Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 5Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 6Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 7Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 8Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 9Health News:Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C 10Health News:New robot-assisted surgical method found successful for treatment of thyroid cancer 2
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... Amvex offers a complete line ... heliox and CO 2 . They ... of calibrations to best suit your ... dials specific to the gas in ...
... Amvex offers a complete line of flowmeters, available ... are all available in a variety of calibrations to ... dials specific to the gas in use, the Amvex ... colors replace the U with I. For Power Take-Off ...
Medicine Products: